Gilead Sciences: Coronary Artery Disease trials
The registry lists 10 Coronary Artery Disease studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 2 3Phase 3 4Phase 4 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)CompletedNCT01442038Phase 3Results posted
- Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable AnginaCompletedNCT01425359Phase 4Results posted
- Study of Ranexa in Patients With Coronary Artery Disease and Painful PolyneuropathyTerminatedNCT00832572Phase 4Results posted
- GS-6615 in Adults With Chronic Stable Angina and Coronary Artery DiseaseWithdrawnNCT02377336Phase 2
- A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)WithdrawnNCT01334203Phase 4
- Ranolazine in Diastolic Heart FailureCompletedNCT01163734Phase 2
- Stress Echocardiography Study With RegadenosonTerminatedNCT00907764Phase 2
- ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)CompletedNCT00208312Phase 3
- ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)CompletedNCT00208299Phase 3
- Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With AmlodipineCompletedNCT00091429Phase 3